Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.IDRA · Entity 110652 | Director | June 23, 2022 | June 27, 2022 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | December 12, 2024 | December 12, 2024 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-06-23 | Direct | 26,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 26,000 · Balance 26,000 F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy. F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.
F2: The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
PALVELLA THERAPEUTICS, INC.
Report date December 12, 2024 · Filed December 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series F Preferred Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 1
1 source rowRow 1 · 2024-12-12 · Disposition to issuer · Disposed 1 · Balance 0 F1: This Form 4 relates to the redemption of the Series F Preferred Stock, par value $0.001, that was issued to James A. Geraghty on August 7, 2024. The Series F Preferred Stock was redeemed by Pieris Pharmaceuticals, Inc. for $0.01 automatically and effective immediately after the effectiveness of its Authorized Share Increase, as set forth in the Certificate of Designation of Series F Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 relates to the redemption of the Series F Preferred Stock, par value $0.001, that was issued to James A. Geraghty on August 7, 2024. The Series F Preferred Stock was redeemed by Pieris Pharmaceuticals, Inc. for $0.01 automatically and effective immediately after the effectiveness of its Authorized Share Increase, as set forth in the Certificate of Designation of Series F Preferred Stock.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JUNIPER PHARMACEUTICALS INC
Report date August 14, 2018 · Filed August 15, 2018
Section 16 reporting ended · disclosed 2018-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 1
1 source rowRow 1 · 2018-08-14 · Disposition to issuer · Disposed 80,747 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2: Includes 15,594 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 15,594 restricted stock units was cancelled in exchange for the Offer Price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.15 · Expires 2024-03-03 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-14 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2022-05-06 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-14 · Disposition to issuer · Disposed 70,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
F2: Includes 15,594 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 15,594 restricted stock units was cancelled in exchange for the Offer Price.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options.
Orchard Therapeutics plc
Report date January 24, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-24 · Disposition to issuer · Disposed 44,391 · Balance 0 F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-24 · Disposition to issuer · Disposed 46,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-24 · Disposition to issuer · Disposed 105,000 · Balance 0 F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.
F2: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
F3: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
F4: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2018 Filed May 16, 2018 13:08 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 10,000 | $5.75 | $57,500.00 |
DisclosureSEC source: 0001562180-18-002509 · primarydocument.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.719 to $5.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 21:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001562180-18-000479 · primarydocument.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:03 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001562180-17-003871 · primarydocument.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-12-12 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on November 15, 2018 and vests as to an additional 6.25% of the option shares at the end of each full fiscal quarter thereafter. Read SEC document |
| August 17, 2017 Filed Aug 17, 2017 23:20 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 10,000 | $4.82 | $48,200.00 |
DisclosureSEC source: 0000899243-17-020636 · doc4.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $4.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:08 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock, par value $0.01 | 15,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043415 · doc4.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,747 F1 · shares: This restricted stock unit award shall vest in full immediately prior to the 2018 annual shareholders meeting. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 17:49 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock, par value $0.01 | 15,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043441 · doc4.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,747 F1 · shares: This restricted stock unit award shall vest in full immediately prior to the 2018 annual shareholders meeting. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042939 · a4.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Geraghty's continued service on the Board of Directors. Read SEC document |
| May 22, 2017 Filed May 25, 2017 00:03 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0000899243-17-014270 · doc4.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2017-05-22 F1 · security: The stock option will vest in four equal quarterly installments on each of June 30, 2017, September 30, 2017, December 31, 2017 and March 31, 2018, subject to the Reporting Person's continued service as a director. F1 · derivative.exercise_date: The stock option will vest in four equal quarterly installments on each of June 30, 2017, September 30, 2017, December 31, 2017 and March 31, 2018, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 16:46 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | PurchaseCommon Stock, par value $0.01 | 2,000 | $4.82 | $9,637.40 |
DisclosureSEC source: 0001209191-17-021759 · doc4.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,153 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.814 to $4.8234, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 17:06 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001209191-17-018818 · doc4.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock, $0.01 par value per share · 30,000 shares Expires 2024-03-03 F1 · derivative.exercise_date: This option will be exercisable as follows: 33.3% on the first two anniversaries of the grant date; and the final 33.4% on third anniversary of grant date. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 17:00 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Purchasecommon stock, par value $0.01 | 2,000 | $5.97 | $11,930.00 |
DisclosureSEC source: 0001382963-16-000238 · edgar.xml · nonDerivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,153 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.962 to $5.968, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 07, 2016 Filed Jun 9, 2017 16:17 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Options · Derivative | 63,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001179110-17-008812 · edgar.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2017-06-07 F1 · security: These options were granted pursuant to the Company's director compensation on the date of the Company's 2017 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2 · derivative.exercise_date: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.